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Phase III Randomized Trial of Chemotherapy With
or Without Bevacizumab in Patients With
Recurrent or Metastatic Head and Neck Cancer
Athanassios Argiris, MD1; Shuli Li, PhD2; Panayiotis Savvides, MD3; James P. Ohr, MD4; Jill Gilbert, MD5; Marshall A. Levine, MD6;
Arnab Chakravarti, MD7; Missak Haigentz Jr, MD8; Nabil F. Saba, MD9; Chukwuemeka V. Ikpeazu, MD, PhD10; Charles J. Schneider, MD11;
Harlan A. Pinto, MD12; Arlene A. Forastiere, MD13; and Barbara Burtness, MD14,15
abstract
PURPOSE We evaluated the addition of bevacizumab, a humanized monoclonal antibody that targets vascular
endothelial growth factor, to platinum-based chemotherapy in recurrent or metastatic squamous cell carcinoma
of the head and neck (SCCHN).
PATIENTS ANDMETHODS Patients with chemotherapy-naı̈ve (or with prior platinum as part of multimodal therapy
completed $ 4 months earlier) recurrent or metastatic SCCHN were randomly assigned to receive a platinum-
based chemotherapy doublet with or without bevacizumab 15 mg/kg given intravenously every 3 weeks until
disease progression. Chemotherapy could be discontinued after six cycles if a maximum response was
achieved.
RESULTS The study randomly assigned 403 patients. Median overall survival (OS) was 12.6 months with
bevacizumab plus chemotherapy (BC) and 11.0 months with chemotherapy alone (hazard ratio, 0.87; 95% CI,
0.70 to 1.09; P = .22). At 2, 3, and 4 years, the OS rates were 25.2% v 18.1%, 16.4% v 10.0%, and 11.8% v
6.4% for BC versus chemotherapy, respectively. In an analysis of 365 eligible patients who started treatment, the
hazard ratio was 0.82 (95% CI, 0.65 to 1.04; P = .10), with a median OS of 14.2 months on BC v 11.1 months on
chemotherapy. Median progression-free survival with BC was 6.0 months v 4.3 months with chemotherapy
(P = .0014). Overall response rates were 35.5% with BC and 24.5% with chemotherapy (P = .016). There was
increased toxicity, including a higher rate of treatment-related grade 3 to 5 bleeding events (6.7% v 0.5%; P ,
.001) and treatment-related deaths (9.3% v 3.5%; P = .022) with BC versus chemotherapy.
CONCLUSION The addition of bevacizumab to chemotherapy did not improve OS but improved the response rate
and progression-free survival with increased toxicities. These results encourage biomarker-driven studies of
angiogenesis inhibitors with better toxicity profiles in select patients with SCCHN.
J Clin Oncol 37:3266-3274. © 2019 by American Society of Clinical Oncology
INTRODUCTION
Historically, . 50% of patients with squamous cell
carcinoma of the head and neck (SCCHN) develop
disease recurrence in either local or distant sites after
potentially curative treatment with surgery and/or ra-
diation with or without chemotherapy. The cornerstone
of treatment in recurrent or metastatic SCCHN remains
platinum-based doublet chemotherapy with a reported
median overall survival (OS) of 6 to 8 months.1 Regimens
with a platinum plus a taxane (paclitaxel or docetaxel)
often are used as treatment options in this setting.2 Until
the introduction of immune checkpoint inhibitors,
cetuximab was the only molecularly targeted therapy with
proven benefit in first-line treatment of recurrent or
metastatic SCCHN. The addition of cetuximab to platinum
(cisplatin or carboplatin) and fluorouracil (FU) improved
OS, progression-free survival (PFS), and the objective
response rate compared with platinum or FU alone.3
However, the 2-year OS rate remained poor at 14%.
Angiogenesis plays a critical role in the development
and growth of SCCHN and has emerged as an im-
portant target for anticancer therapy.4 Increased ex-
pression of vascular endothelial growth factor (VEGF),
a potent inducer of angiogenesis, has been linked to
poor prognosis in SCCHN.5 Ameta-analysis concluded
that patients whose primary tumors overexpressed
VEGF, as measured by immunochemistry, had a 1.88-
fold higher mortality.6
Bevacizumab is an anti-VEGF, humanizedmonoclonal
antibody that has been used in the treatment of several
advanced solid tumors, including colorectal, non–small-
cell lung, ovarian, and cervical cancers, in combination
with chemotherapy. Preclinical studies in SCCHN sup-
port the combination of a taxane and bevacizumab.7
Paradoxically, bevacizumab may stabilize and mature
tumor vasculature, which leads to lower interstitial fluid
pressure and increased tumor blood flow. This may
reduce tumor hypoxia and lead to improved delivery of
chemotherapy to tumor tissue, thereby providing
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a potential mechanism for the synergistic effect of bev-
acizumab with other systemic agents.4,8 In the clinic,
a number of phase II trials have explored bevacizumab-based
combinations in recurrent or metastatic SCCHN.9-11 A study
that investigated the combination of pemetrexed and bev-
acizumab reported promising efficacy results with a median
OS of 11.3 months but with a relatively high rate of hemor-
rhagic complications (15% with grade $ 3).9 On the other
hand, a clinical trial of cetuximab and bevacizumab in re-
current or metastatic SCCHN did not report a concerning rate
of hemorrhage.10
We conducted a phase III study (E1305; ClinicalTrials.gov
identifier: NCT00588770) coordinated by the Eastern
Cooperative Oncology Group (ECOG)-American College of
Radiology Imaging Network Cancer Research Group that
compared investigator’s-choice platinum-based doublet
with or without bevacizumab in patients with recurrent or
metastatic SCCHN. The primary objective of this study was
to evaluate the OS.
PATIENTS AND METHODS
Eligibility
Adult patients with an ECOG performance status of 0 to 1
and adequate end organ function with pathologically
confirmed SCCHN from any primary site, including un-
known primary lymphadenopathy of the head and neck,
were eligible; those with nonkeratinizing nasopharyngeal
carcinoma or squamous cell carcinoma that originated in
the skin were excluded. SCCHN was either metastatic or
recurrent and judged incurable by surgery or radiation.
Patients who refused radical surgery for recurrent disease
were eligible. Measurable disease by RECIST with baseline
scans obtained # 4 weeks before randomization was
required. No prior chemotherapy or biologic/molecular-
targeted therapy for recurrent or metastatic SCCHN was
permitted. Prior chemotherapy or cetuximab as part of
initial potentially curative therapy was allowed if completed
$ 4 months previously and if patients had remained
progression free for at least 4 months after completion of
this therapy. Patients with tumors that unequivocally in-
vaded major vessels or central cavitary lung metastases
were excluded. Patients were not permitted to have a his-
tory of thrombosis requiring anticoagulation, bleeding
associated with SCCHN, or gross hemoptysis. No prior
treatment with bevacizumab was allowed. A maximum of
one prior radiotherapy regimen, curative or palliative, to the
head and neck was allowed. Furthermore, the trial ex-
cluded patients who received chronic daily treatment with
aspirin or nonsteroidal anti-inflammatory agents known
Recurrent or metastatic
SCCHN
(N = 403)
Follow-up status as of June 5, 2018
    No follow-up, withdrew consent
    Follow-up submitted
    Documented lost to follow-up
(n = 0)
(n = 200)
(n = 1)
Follow-up status as of June 5, 2018
    No follow-up, withdrew consent
    Follow-up submitted
    Documented lost to follow-up
(n = 0)
(n = 203)
(n = 12)
Randomly assigned to chemotherapy
(n = 200)
Randomly assigned to BC
(n = 203)
In primary efficacy analysis
In toxicity analysis
(n = 200)
(n = 199)
In primary efficacy analysis
In toxicity analysis
(n = 203)
(n = 193)
Ineligible
      Invalid baseline scans
      Ineligible histology
      Prior treatment
      Invalid laboratory results
      Other
(n = 12)
(n = 3)
(n = 3)
(n = 2)
(n = 2)
(n = 2)
Ineligible
       Invalid baseline scans
       Ineligible histology
       Prior treatment
       Invalid laboratory results
       Other
(n = 20)
(n = 8)
(n = 1)
(n = 4)
(n = 3)
(n = 4)
Did not start treatment
(n = 0)
Did not start treatment
       Medical decision
       Patient ineligible
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       Death
(n = 9)
(n = 4)
(n = 2)
(n = 2)
(n = 1)
FIG 1. CONSORT diagram of
study E1305. BC, bevacizumab
plus chemotherapy; SCCHN,
squamous cell carcinoma of the
head and neck.
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TABLE 1. Patient Characteristics
Chemotherapy
(n = 200) BC (n = 203) Total (N = 403)
Characteristic No. % No. % No. %
Sex
Male 168 84.0 176 86.7 344 85.4
Female 32 16.0 27 13.3 59 14.6
Age, years
, 70 179 89.5 176 86.7 355 88.1
$ 70 21 10.5 27 13.3 48 11.9
Race
White 168 87.0 179 89.9 347 88.5
Black 21 10.9 18 9.0 39 9.9
Asian 0 0.0 1 0.5 1 0.3
Native American 2 1.0 1 0.5 3 0.8
Multirace 2 1.0 0 0.0 2 0.5
Not reported 7 4 11
Chemotherapy assignment
Cisplatin plus docetaxel 95 47.5 99 48.8 194 48.1
Carboplatin plus docetaxel 80 40.0 78 38.4 158 39.2
Cisplatin plus fluorouracil 14 7.0 17 8.4 31 7.7
Carboplatin plus fluorouracil 11 5.5 9 4.4 20 5.0
Ethnicity
Hispanic 11 5.9 11 5.6 22 5.7
Non-Hispanic 177 94.1 185 94.4 362 94.3
Not reported 12 7 19
Primary site
Oral cavity 44 22.0 41 20.2 85 21.1
Nasopharynx 2 1.0 5 2.5 7 1.7
Oropharynx 76 38.0 87 42.9 163 40.4
Hypopharynx 11 5.5 4 2.0 15 3.7
Larynx 45 22.5 46 22.7 91 22.6
Salivary glands 4 2.0 1 0.5 5 1.2
Paranasal sinuses 3 1.5 2 1.0 5 1.2
Nose 1 0.5 1 0.5 2 0.5
No primary identified 5 2.5 3 1.5 8 2.0
Other 3 1.5 4 2.0 7 1.7
Multiple primary 6 3.0 9 4.4 15 3.7
Histologic grade
Well differentiated 14 7.0 18 8.9 32 7.9
Moderately differentiated 87 43.5 82 40.4 169 41.9
Poorly differentiated 73 36.5 73 36.0 146 36.2
Undifferentiated 2 1.0 8 3.9 10 2.5
Grade cannot be assessed 24 12.0 22 10.8 46 11.4
(continued on following page)
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to inhibit platelet function, patients with uncontrollable
hypertension or active heart disease, and patients with
hypercalcemia related to head and neck cancer.
All patients provided written informed consent. The study
was approved by the ethics committee of each participating
center and was conducted in compliance with the Dec-
laration of Helsinki.
Study Design
Patients were equally assigned randomly between the two
treatment arms. On the basis of a previous analysis of
ECOG-American College of Radiology Imaging Network
trials,12 stratification factors were as follows: chemotherapy
regimen, performance status, prior radiation to the head
and neck, and weight loss in the past 6 months (, 5% v
$ 5%). Randomization was done using permuted blocks
within strata, with dynamic balancing within main in-
stitutions and their affiliate networks. The primary study end
point was OS. Secondary efficacy end points were PFS,
objective response, and toxicity.
The design called for a total accrual of 400 patients to give
full information of 354 deaths to provide 80% power to
detect a 26% reduction in the hazard rate (corresponding
to an improvement in median survival from 8.5 to 11.5
months) using a one-sided test with an overall type I error
rate of 2.5%. Interim analyses were planned for all semi-
annual data safety monitoring committee meetings, which
started when 25% of the information (89 deaths) was
available. The trial was monitored according to princi-
ples of group sequential methods using a one-sided
TABLE 1. Patient Characteristics (continued)
Chemotherapy
(n = 200) BC (n = 203) Total (N = 403)
Characteristic No. % No. % No. %
Disease status
Recurrent 45 22.5 40 19.7 85 21.1
Metastatic 96 48.0 119 58.6 215 53.3
Recurrent and metastatic 59 29.5 44 21.7 103 25.6
ECOG PS
0 86 43.0 85 41.9 171 42.4
1 114 57.0 118 58.1 232 57.6
Prior RT to head and neck
No 35 17.5 39 19.2 74 18.4
Yes 165 82.5 164 80.8 329 81.6
Prior chemotherapy
No 87 43.5 75 36.9 162 40.2
Yes 113 56.5 128 63.1 241 59.8
Prior chemotherapy # 12 months 51 50 101
Prior chemotherapy . 12 months 55 73 128
Unknown timing 7 5 12
Weight loss in previous 6 months, %
, 5 137 68.5 127 62.6 264 65.5
5 to , 10 24 12.0 44 21.7 68 16.9
10 to , 20 35 17.5 26 12.8 61 15.1
$ 20 4 2.0 6 3.0 10 2.5
Smoking history
Never smoked 34 17.4 41 20.6 75 19.0
Pipe or cigar smoker only 5 2.6 6 3.0 11 2.8
Cigarette smoker, , 20 pack-years 28 14.4 30 15.1 58 14.7
Cigarette smoker, 20-40 pack-years 52 26.7 54 27.1 106 26.9
Cigarette smoker, . 40 pack-years 76 39.0 68 34.2 144 36.5
Unknown 5 4 9
Abbreviations: BC, bevacizumab plus chemotherapy; ECOG PS, Eastern Cooperative Oncology Group performance status; RT, radiotherapy.
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O’Brien-Fleming upper boundary to preserve the overall type I
error of 0.025. The rates of grade 3 to 5 bleeding events also
were monitored continuously by the data safety and moni-
toring committee, and the difference between the treatment
arms was assessed after every 100 patients were enrolled
using one-sided Fisher’s exact tests with a nominal type I
error of 0.05. Suspension of the trial could be considered if
there was a significant difference between the arms. Archival
tumor tissue and blood samples were collected at baseline
and after one cycle of therapy for future correlative studies.
Treatment
Patients were randomly assigned to receive either
a platinum-containing chemotherapy doublet or a platinum-
containing chemotherapy doublet plus bevacizumab
(BC). Each treatment cycle was 21 days. Patients could
receive one of the following regimens according to in-
vestigator discretion before randomization: docetaxel
75 mg/m2 intravenously (IV) over 1 hour, day 1, followed by
cisplatin 75 mg/m2 IV over 1 to 2 hours, day 1, every 21
days; docetaxel 75 mg/m2 IV over 1 hour, day 1, followed by
carboplatin area under the curve 6 over 30 minutes, day 1,
every 21 days; cisplatin 100mg/m2 IV over 1 to 2 hours, day
1, followed by FU 1,000 mg/m2/d as a continuous infusion
3 4 days every 21 days; or carboplatin area under the curve
6 over 30 minutes, day 1, followed by FU 1,000 mg/m2/d as
a continuous infusion 3 4 days every 21 days. Bev-
acizumab 15 mg/kg IV was given on day 1 of each cycle. All
patients received prophylactic antibiotics with chemo-
therapy. Growth factor use was allowed per ASCO guide-
lines. Treatment continued until disease progression or
intolerable toxicity in both arms. However, chemotherapy
could be discontinued beyond the sixth cycle if maximum
response was achieved (ie, no improvement in tumor
measurements for two or more cycles). For patients who
were randomly assigned to BC, bevacizumab was con-
tinued until disease progression.
Statistical Analyses
The primary, intention-to-treat, analysis was based on all
randomly assigned patients. Survival was defined as the
time from randomization to death as a result of any cause,
with follow-up censored at the date of last contact. Ob-
jective response was evaluated using the original RECIST.
PFS was defined as the time from randomization to
documented progression or death without progression.
Patients without documented progression or death re-
ported were censored at the time of the last documented
disease evaluation. Kaplan-Meier estimates were used for
event-time distributions. OS and PFS were compared using
log-rank tests stratified by chemotherapy regimen, per-
formance status, prior radiation to the head and neck, and
weight loss in the past 6 months (as available in the ran-
domization). Stratified Cox proportional hazards regression
models were used to estimate hazard ratios (HRs). Adverse
events, patient demographics, disease characteristics, and
response rates were compared using Fisher’s exact test. P
values are two-sided and CIs are at the 95% level. Detailed
adverse events were recorded with National Cancer In-
stitute Common Terminology Criteria for Adverse Events
(version 4.0).
RESULTS
Patient Characteristics
The study was activated in August 2008 and closed in
February 2015, with a total accrual of 403 patients (200 in
the chemotherapy arm and 203 in the BC arm). This final
report is based on data available as of June 5, 2018. The
median follow-up of alive patients was 40 months. Thirty-
two patients were ineligible; nine patients in the BC arm
never started protocol therapy. All 403 randomly assigned
patients were included in the primary analysis. Among
all patients, two (one in each arm) were documented as lost
to follow-up. Figure 1 shows the CONSORT diagram of
this study.
Patient demographics and disease characteristics of all
randomly assigned patients at study entry are listed in
Table 1. The most common primary site was the oro-
pharynx (40.4%) followed by the larynx (22.6%) and the
oral cavity (21.1%). Approximately 82% of patients had
received prior radiation therapy to the head and neck, and
60% of patients had received prior chemotherapy. The
majority of patients (87.3%) received docetaxel (cisplatin
and docetaxel or carboplatin and docetaxel) as the in-
vestigator’s choice regimen in E1305. All baseline factors
were well balanced between the two arms. Twenty-five
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BC (175 events/203 patients)
P = .22
Chemotherapy 200 145 90 53 35 24 17 14 9
BC 203 145 100 73 46 36 29 22 16
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No. at risk:
FIG 2. Kaplan-Meier estimates of overall survival by treatment arm.
Themedian overall survival was 12.6 months with bevacizumab plus
chemotherapy (BC) and 11.0 months with chemotherapy alone
(hazard ratio, 0.87; 95% CI, 0.70 to 1.09; P = .22).
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patients (12.5%) in the chemotherapy arm and 35 (17.2%)
in the BC arm had previously received cetuximab as part of
multimodal treatment of locally advanced disease (P = .21).
Treatment Delivery
The distribution of number of cycles reported by arm and
sex is listed in Appendix Table A1 (online only). Patients
who never started treatment were excluded for this analysis.
The median number of treatment cycles given was four in
both arms. Twenty-seven percent of patients in the BC arm
received maintenance bevacizumab after six cycles, with
13% of patients receiving . 1 year of therapy. Of the 53
patients in arm BC who received more than six cycles of
protocol treatment, 39 received bevacizumab only, 11
received BC, and three received chemotherapy only.
Whether a patient continued protocol treatment beyond six
cycles did not depend on which chemotherapy doublet
they received.
OS
At the time of analysis, 357 of 403 patients in the primary
analysis had died (182 in the chemotherapy arm, 175 in
the BC arm). Figure 2 shows OS by treatment in the
primary analysis. OS was not significantly different be-
tween the two arms. Themedian OS was 11.0 months with
chemotherapy and 12.6 months with BC (P = .22). The
estimated OS HR (BC/chemotherapy) was 0.87 (95% CI,
0.70 to 1.09). The 2-, 3-, and 4- OS in the BC versus
chemotherapy arms were 25.2% v 18.1%, 16.4% v
10.0%, and 11.8% v 6.4%, respectively. In an analysis
that excluded patients who were either ineligible or never
started protocol treatment (12 in the chemotherapy arm
and 26 in the BC arm), the P value from the log-rank test
for OS was .10 with an estimated HR (BC/chemotherapy)
of 0.82 (95% CI, 0.65 to 1.04); the median OS in these
365 patients (188 in the chemotherapy arm and 177 in
Group
All patients 
Male
Female
Age  70 years
Age  70 years
Weight loss  5%
Weight loss  5%
Smoking history  20 pack-years
Smoking history  20 pack-years
Oral cavity
Oropharynx
Larynx
Other
Histology well or moderately differentiated
Histology poorly differentiated or undifferentiated
Cannot be assessed
ECOG PS 0
ECOG PS 1
Cisplatin plus docetaxel
Cisplatin plus fluorouracil
Carboplatin plus docetaxel
Carboplatin plus fluorouracil
No prior RT
Prior RT
No prior chemotherapy
Prior chemotherapy  12 months
Prior chemotherapy > 12 months
No prior cetuximab
Prior cetuximab
Recurrent
Metastatic
Recurrent and metastatic
No.
403
344
59
355
48
264
139
144
250
85
163
91
64
201
156
46
171
232
194
31
158
20
74
329
162
101
128
343
60
85
215
103
HR
0.87
0.83
0.91
0.84
0.67
0.75
0.93
0.66
0.92
0.81
0.80
1.02
0.78
0.94
0.73
0.68
0.78
0.84
0.70
0.66
1.12
0.62
0.72
0.86
0.73
1.31
0.78
0.80
1.02
1.05
0.85
0.77
95% CI
0.70 to 1.09
0.66 to 1.03
0.52 to 1.60
0.67 to 1.05
0.37 to 1.23
0.58 to 0.98
0.65 to 1.32
0.46 to 0.94
0.71 to 1.19
0.51 to 1.29
0.57 to 1.12
0.66 to 1.57
0.46 to 1.32
0.71 to 1.26
0.52 to 1.03
0.35 to 1.33
0.56 to 1.09
0.64 to 1.10
0.52 to 0.96
0.31 to 1.43
0.80 to 1.55
0.24 to 1.60
0.44 to 1.20
0.68 to 1.08
0.53 to 1.02
0.87 to 1.97
0.54 to 1.14
0.64 to 1.00
0.59 to 1.78
0.67 to 1.65
0.64 to 1.13
0.50 to 1.18
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FIG 3. Forest plot of overall survival treatment hazard ratios (HRs; bevacizumab and chemotherapy [BC]/chemotherapy) in patient subgroups. ECOG PS,
Eastern Cooperative Oncology Group performance status; RT, radiotherapy.
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the BC arm) was 11.1 months with chemotherapy and
14.2 months with BC.
Figure 3 shows a forest plot of OS for various patient
subgroups. In exploratory analyses, the test for the in-
teraction of treatment by prior chemotherapy (received
# 12 months v none or received . 12 months) in a Cox
proportional hazards regression model had P = .021, al-
though we emphasize that this result should be interpreted
with caution given the ad hoc nature of the analysis. All
other interactions were not significant.
PFS and Objective Response
PFS by treatment is shown in Figure 4. The median PFS
was 6.0 months with BC and 4.3 months with chemo-
therapy (P = .0014). The estimated PFS HR (BC/chemo-
therapy) was 0.70 (95% CI, 0.57 to 0.87). The 2-, 3-, and
4- PFS rates in the BC arm versus chemotherapy arm were
7.1% v 2.1%, 5.5% v 0.5%, and 3.7% v 0.5%, respectively.
In the chemotherapy arm, only one patient (with oropha-
ryngeal primary) achieved a 3-year PFS (censored at 48
months), whereas in the BC arm, 10 patients (nine with
oropharyngeal primary, one with oral cavity primary) had
a PFS of at least 3 years, among whom four had a PFS
. 4 years (all with oropharyngeal primary). In an analysis
that excluded patients who were either ineligible or never
started protocol treatment, the P value from the log-rank
test for PFS was , .001 with an estimated HR (BC/che-
motherapy) of 0.68 (95% CI, 0.53 to 0.85).
Best response by treatment is listed in Appendix Table A2
(online only). The overall response rate (complete response
rate plus partial response rate) was higher in the BC arm
(35.5% with BC v 24.5% with chemotherapy; P = .016).
Toxicity
The toxicity analysis included 392 patients (199 in the
chemotherapy arm and 193 in the BC arm), excluding nine
patients in the BC arm who never started treatment and two
additional patients whose toxicity was not assessed (one in
each arm). Treatment-related adverse events by treatment
arm are listed in Table 2 (except for bleeding events, which
were examined separately). Grade $ 3 events were sig-
nificantly higher in the BC arm for oral mucositis (P, .001),
hypertension (P , .001), dehydration (P = .001), throm-
boembolic event (P = 0.005), diarrhea (P = .01), dysphagia
(P = .01), febrile neutropenia (P = .02), leukopenia
(P = .02), neutropenia (P = .02), abdominal pain (P = .03),
fatigue (P = .04), and worst degree of toxicity (P , .001).
The incidence of grade $ 3 hemorrhage and death during
the study are listed in Table 3. Treatment-related grade$ 3
bleeding was significantly more common with BC versus
chemotherapy (6.7% v 0.5%; P , .001). There were 18
grade 5 events in the BC arm (9.3%) and seven grade 5
events in the chemotherapy arm (3.5%) that were classified
as at least possibly a result of treatment (P = .02). Of these
events, grade 5 bleeding events were reported in 2.6% of
patients treated with BC and none treated with chemo-
therapy. All treatment-related deaths occurred in the first
6 months.
Chemotherapy (193 events/200 patients)
BC (190 events/203 patients)
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FIG 4. Kaplan-Meier estimates of progression-free survival by treatment
arm. The median progression-free survival was 6.0 months with bev-
acizumab plus chemotherapy (BC) and 4.3 months with chemotherapy
alone (estimated hazard ratio, 0.70; 95% CI, 0.57 to 0.87; P = .0014).
TABLE 2. Grade 3 to 4 Toxicities (except bleeding)
Chemotherapy
(n = 199), % BC (n = 193), %
Toxicity Type Grade 3 Grade 4 Grade 3 Grade 4
Anemia 8.0 1 4 1.0
Neutropenia* 0.5 26 7 31.0
Leukopenia* 3.0 14 5 22.0
Febrile neutropenia* 7.0 3 11 7.0
Fatigue* 10.0 — 18 —
Diarrhea* 0.5 — 5 —
Dysphagia* 0.5 — 5 —
Oral mucositis* 4.0 — 19 —
Nausea 8.0 — 11 —
Vomiting 5.0 — 7 0.5
Anorexia 7.0 — 6 —
Abdominal pain* 0.5 4
Dehydration* 6.0 — 15 0.5
Hypertension* — — 6 —
Thromboembolic event* 0.5 — 5 0.5
Worst degree*† 31.0 34 34 41.0
Abbreviation: BC, bevacizumab plus chemotherapy.
*P , .05 for the comparison between the two arms.
†Worst degree toxicity includes bleeding.
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DISCUSSION
This was a large, phase III, multicenter trial in the first-line
treatment setting of patients with recurrent or metastatic
SCCHN. The addition of bevacizumab to a platinum-based
doublet did not improve OS but did improve PFS and re-
sponse rate. The median survival was 12.6 months in the
BC arm and 11.0 months in the chemotherapy arm (HR,
0.87; 95% CI, 0.70 to 1.09; P = .22). Although a statistically
significant improvement in OS was not reached, there was
noted numerical survival advantage at 2, 3, 4, and 5 years
in the BC arm (25.2% v 18.1%, 16.4% v 10.0%, 11.8% v
6.4%, and 7.2% v 4.0%, respectively). Moreover, median
PFS improved from 4.3 to 6.0 months (HR, 0.70; P =
.0014), and the response rate increased from 24.5% to
35.5% (P = .016) with BC. Survival in the chemotherapy
arm was markedly better than expected, which could
be explained by various factors, including the use of
docetaxel in the regimen, increased incidence of human
papillomavirus–associated oropharyngeal tumors, improve-
ments in supportive care, and the potential impact of
subsequent lines of therapy. Cetuximab became US Food
and Drug Administration approved for recurrent or meta-
static SCCHN during this study. We did not collect sub-
sequent treatment information, and whether second-line
cetuximab played a role in the OS results reported cannot
be assessed. Moreover, we note that as in most other
bevacizumab randomized trials, this was not a placebo-
controlled trial. Whether the lack of placebo affected any of
the efficacy parameters examined or the toxicity reporting is
not possible to ascertain.
Despite our careful exclusion criteria aimed at reducing the
chances of treatment-related bleeding and the use of
antibiotic prophylaxis, we observed a significant increase in
treatment-related toxicities with bevacizumab, including
grade 3 to 5 bleeding, oral mucositis, dysphagia, diarrhea,
fatigue, febrile neutropenia, and thromboembolic events. It
is possible that the increased number of treatment-related
deaths in the BC arm that occurred in the first 6 months
affected our ability to demonstrate a survival difference
between the two arms. After the first few months, the OS
curves separated in favor of the BC arm, and at 3 and
4 years, there were approximately twice as many long-term
survivors with BC versus chemotherapy alone. Given this
encouraging finding as well as the better PFS and response
rates with the addition of bevacizumab to standard che-
motherapy doublets, the VEGF pathway appears to be
a relevant therapeutic target in SCCHN. Better tolerated
anti-VEGF pathway agents that are not associated with high
rates of bleeding may be considered in future clinical trials
in SCCHN. Individualized anti-angiogenic treatment on the
basis of molecular tumor characterization is desirable and
may lead to improved outcomes. Because tissue and blood
samples have been collected in the context of E1305, this
will be the subject of future analysis from our group.
In conclusion, this study indicates that the addition of
bevacizumab to chemotherapy improves PFS and re-
sponse rates but increases toxicities in the first-line treat-
ment of patients with recurrent or metastatic SCCHN.
We observed a small, but not statistically significant,
improvement in OS. Although the study may have been
underpowered because of the longer survival in the che-
motherapy arm, the identification of patient characteristics
and biomarkers for survival benefit will be critical for further
development of this strategy in SCCHN. On the basis of the
results of E1305, we believe that the targeting of angio-
genesis remains an attractive strategy, and further inves-
tigation of agents that target the VEGF pathway in SCCHN is
justifiable.
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APPENDIX
TABLE A1. Number of Cycles Delivered in Each Arm
Cycles, No. Chemotherapy (n = 200), No. (%) BC (n = 203), No. (%)
1 25 (12.5) 27 (13.9)
2 32 (16) 32 (16.5)
3 8 (4) 19 (9.8)
4 36 (18) 24 (12.4)
5 13 (6.5) 13 (6.7)
6 65 (32.5) 26 (13.4)
7-10 21 (10.5) 28 (14.4)
11-15 0 (0) 11 (5.6)
17-20 0 (0) 9 (4.5)
23-54 0 (0) 5 (2.5)
Abbreviation: BC, bevacizumab plus chemotherapy.
TABLE A2. Best Objective Response by Treatment Arm
Response
Chemotherapy (n = 200),
No. (%) BC (n = 203), No. (%)
Overall response rate (complete response plus
partial response), % (95% CI)*
24.5 (18.7 to 31.0) 35.5 (28.9 to 42.5)
Complete response 2 (1.0) 11 (5.4)
Partial response 47 (23.5) 61 (30.1)
Stable disease 75 (37.5) 58 (28.6)
Progression 39 (19.5) 27 (13.3)
Unevaluable 37 (18.5) 46 (22.7)
Abbreviation: BC, bevacizumab plus chemotherapy.
*P = .016 for the comparison between the two arms.
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